Managing Myeloma

Planning Treatment Strategies for Older Adults with Myeloma: Considerations for Assessment of the Elderly/Frail Patient

References

1. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. *J Clin Oncol.* 2007;25(15):1993-1999. doi:10.1200/JCO.2006.09.0100

2. Huang LW, Bacon W, Cirrincione C, et al. Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. *Hematol Oncol.* 2017;35(4):752-759. doi:10.1002/hon.2379

3. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. *Blood*. 2015;125(13):2068-2074. doi:10.1182/blood-2014-12-615187

4. http://www.myelomafrailtyscorecalculator.net/

5. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. *J Clin Oncol*. 2011;29(25):3457-3465. doi:10.1200/JCO.2011.34.7625

6. Tuchman SA, Moore JO, DeCastro CD, et al. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. *J Geriatr Oncol.* 2017;8(3):165-169. doi:10.1016/j.jgo.2017.02.004

7. Guerard EJ, Deal AM, Chang Y, et al. Frailty Index Developed From a Cancer-Specific Geriatric Assessment and the Association With Mortality Among Older Adults With Cancer. *J Natl Compr Canc Netw.* 2017;15(7):894-902. doi:10.6004/jnccn.2017.0122

8. Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. *Haematologica.* 2017;102(5):910-921. doi:10.3324/haematol.2016.162693

9. Isaacs A, Fiala M, Tuchman S, et al. A comparison of three different approaches to defining frailty in older patients with multiple myeloma. *J Geriatr Oncol.* 2020;11(2):311-315. doi:10.1016/j.jgo.2019.07.004

10. Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. *J Clin Oncol.* 2018;36(22):2326-2347. doi:10.1200/JCO.2018.78.8687

11. International Society of Geriatric Oncology (SIOG). Comprehensive Geriatric Assessment (CGA) of the older patient with cancer. Accessed February 5, 2021. http://www.siog.org/content/comprehensive-geriatric-assessment-cga-older-patient-cancer

12. Bortezomib [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals, Inc.; 2019.

13. Carfilzomib [prescribing information]. Thousand Oaks, CA: Onyx Pharmaceuticals, Inc.; 2020.

14. Mateos MV, San Miguel JF. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. *Ther Adv Hematol*. 2012;3(2):117-124. doi:10.1177/2040620711432020

15. Yao R, Hu X, Zhou S, et al. Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China. *Medicine (Baltimore)*. 2019;98(39):e17147. doi:10.1097/MD.0000000000017147

16. O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. *Br J Haematol.* 2018;182(2):222-230. doi:10.1111/bjh.15261

17. Vickrey E, Fellingham S, Mehta J, et al. Acyclovir To Prevent Herpes Zoster in Myeloma Patients Treated with Bortezomib. *Blood.* 2007;110 (11):4807.